Andere talen Immutep ADR Deutsche Boerse AG

Aandelen

YP1A

US45257L1089

Beurs gesloten - Deutsche Boerse AG Andere beurzen 08:05:16 14-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,5 ^EUR	+6,84%		-0,79%	+17,92%

05/06	Immutep rondt aanbieding van aandelen af	MT
03/06	Immutep Limited kondigt een klinische samenwerking aan met Msd om Efti te evalueren in combinatie met Keytruda®? (Pembrolizumab) in een Pivotaal Fase Iii Onderzoek	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Immutep Completes Stock Offering	05/06
Immutep : successfully completes institutional placement and institutional component of entitlement offer	05/06
Immutep, Merck Collaborate on Trial for Lung Cancer Therapy	03/06
Immutep, Merck Partner for Efti and Keytruda Combo in Lung Cancer Trial	03/06
Immutep Raising AU$100 Million for Phase Three Trial	03/06
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial	03/06
Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial	03/06
Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data	15/05
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024	15/05
Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024	15/05
Immutep : ESMO Breast 2024 AIPAC 003 Poster (Metastatic Breast Cancer)	15/05
Immutep Limited Announces Initial Clinical Data from EFTISARC-NEO	03/05
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	02/05
Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	02/05
Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial	02/05
Immutep Limited Provides an Update on the Ongoing Development of its Product Candidates, eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2024	30/04
Immutep Quarterly Activities Report Q3 FY24	29/04
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Phase IIb Trial Evaluating Efti in Combination With KEYTRUDA in First Line Metastatic Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression	25/04
Immutep Shows Positive Data in Trial to Treat Squamous Cell Cancers in Head, Neck	24/04
Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B	24/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Immutep ADR Deutsche Boerse AG

Aandelen

YP1A

US45257L1089

Andere talen

Filters